EPOCH-R

DRUG2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Burkitt LymphomaDiffuse Large B-cell Lymphoma, c-MYC PositiveLymphoma, Mantle CellMantle Cell LymphomaPlasmablastic Lymphoma

Phase 2

Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma

CompletedNCT00005780

National Cancer Institute (NCI)Lymphoma, Mantle Cell, Mantle Cell Lymphoma

Start: 2000-06-01End: 2021-06-16Updated: 2023-01-31

Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

CompletedNCT01092182

National Cancer Institute (NCI)Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma

Start: 2010-03-25End: 2023-02-16Updated: 2023-04-27

Related Papers

Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment

Blood Advances2022-07-2715 citations

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma

Journal of Clinical Oncology2020-05-26146 citations

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

2018-12-01161 citations

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R

Blood2015-12-0315 citations

John Leonard Tweets Top 10 Lymphoma Abstracts Countdown to #ASH14

Oncology Times2015-01-01

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

Blood2014-12-0655 citations

Concurrent Expression Of MYC/BCL2 Protein In Newly Diagnosed DLBCL Is Not Associated With An Inferior Survival Following EPOCH-R Therapy

Blood2013-11-1515 citations